Walleye Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Walleye Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,200	Closed	-$44.3K	–	4959
2026 Q1	$44.3K	Buy	+2,200	New	+$35.5K	﹤0.01%	3929
2025 Q3	–	Sell	-21,400	Closed	-$242K	–	4812
2025 Q2	$242K	Buy	+21,400	New	+$262K	﹤0.01%	3214

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's KALV Position: Q2 2026 in Review

Walleye Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 79,666 shares — an estimated $1.6M sold.

Walleye Capital first reported a position in KALV in Q1 2020 and held it in 12 quarters. The position peaked at $2.88M in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Walleye Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 79,666 KalVista Pharmaceuticals shares in Q2 2026, an estimated $1.6M.
Walleye Capital first reported a position in KalVista Pharmaceuticals in Q1 2020 and held it in 12 quarters.
Walleye Capital's KalVista Pharmaceuticals position peaked at $2.88M in Q1 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.